FLNA
Filana Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $24 | $1.19 | -95% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $25 | $1.19 | -95% |
| Millennium Management re-entered | Q1 2025(8Q snapshot) | 5Q | $2.42 | $1.19 | -51% |
| D.E. Shaw | Q1 2026(8Q snapshot) | 1Q | $2.09 | $1.19 | -43% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $2.09 | $1.19 | -43% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 3× in & out | Q4 2025 | Q1 2026 | → $2.09 | -24% |
| AQR Capital Management | Q2 2025 | Q4 2025 | → $2.76 | +35% |
| Greenlight Capital | Q1 2022 | Q2 2022 | — | +0% |
| Maverick Capital | Q3 2021 | Q4 2021 | → $61 | -48% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at FILANA THERAPEUTICS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Nov 25, 2025 — the most recent Form 4 on file — not from today.
- Form 40001437749-25-036321Nov 25, 2025
- Form 40001437749-25-036125Nov 24, 2025
- Form 40001437749-25-035882Nov 20, 2025
- Form 40001437749-25-031540Oct 22, 2025
- Form 40001437749-25-030348Oct 2, 2025
- Form 40001437749-25-029725Sep 23, 2025
- Form 40001437749-25-029586Sep 22, 2025
- Form 40001437749-25-022829Jul 16, 2025
- Form 40001437749-25-018505May 27, 2025
- Form 40001437749-25-018503May 27, 2025
- Form 40001437749-25-018500May 27, 2025
- Form 40001437749-25-018497May 27, 2025
- Form 40001437749-25-018494May 27, 2025
- Form 40001437749-25-012557Apr 21, 2025
- Form 40001437749-25-012554Apr 21, 2025
Fundamentals
XBRL · Filana Therapeutics, Inc.Annual figures sourced directly from Filana Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for FILANA THERAPEUTICS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QFORM 10-QMay 7, 2026
- 8-KFORM 8-KMay 7, 2026
- DEF 14AFORM DEF 14AApr 28, 2026
- 8-KFORM 8-KApr 28, 2026
- 10-KFORM 10-KMar 12, 2026
- 8-KFORM 8-KMar 12, 2026
- 8-KFORM 8-KMar 10, 2026
- 8-KFORM 8-KFeb 19, 2026
- 8-KFORM 8-KDec 23, 2025
- 8-K/AFORM 8-K/ADec 22, 2025
- 8-KFORM 8-KDec 18, 2025
- 8-KFORM 8-KDec 17, 2025
- 8-KFORM 8-KDec 3, 2025
- S-3Registration (shelf)Nov 13, 2025
- 10-QFORM 10-QNov 12, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $1.24 | $1.19 | -4% |
| D.E. Shaw | Q1 2026 | open | $2.09 | $1.19 | -43% |
| Point72 Asset Management | Q1 2026 | open | $2.09 | $1.19 | -43% |
| Citadel Advisors | Q4 2025 | Q1 2026 | $2.76 | $2.09 | -24% |
| Millennium Management | Q3 2025 | open | $2.41 | $1.19 | -51% |
| Citadel Advisors | Q2 2025 | Q3 2025 | $2.05 | $2.41 | +18% |
| AQR Capital Management | Q2 2025 | Q4 2025 | $2.05 | $2.76 | +35% |
| Millennium Management | Q1 2025 | Q2 2025 | $2.42 | $2.05 | -15% |
| Renaissance Technologies | Q4 2024 | Q1 2025 | $25 | $2.38 | -91% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $24 | $26 | +10% |
| Two Sigma Investments | Q3 2024 | open | $24 | $1.19 | -95% |
| Greenlight Capital | Q1 2022 | Q2 2022 | $0.00 | — | +0% |
| Maverick Capital | Q3 2021 | Q4 2021 | $117 | $61 | -48% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.